Market Spotlight: Systemic Lupus Erythematosus (SLE)
Market Spotlight: Systemic Lupus Erythematosus (SLE)
$1,318.00
This Market Spotlight report covers the SLE market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, upcoming and regulatory events, probability of success, patent information, epidemiology information, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts
Author: Informa Pharma Intelligence
Publisher: Datamonitor Healthcare
- Description
- Contents
This Market Spotlight report covers the SLE market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, upcoming and regulatory events, probability of success, patent information, epidemiology information, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways
- The approved drugs in the systemic lupus erythematosus (SLE) space target B-cell activating factor, glucocorticoid receptor, corticotropin releasing factor, and corticotropin releasing hormone. These drugs are administered via the subcutaneous, intravenous, intramuscular, and oral routes.
- The majority of industry-sponsored drugs in active clinical development for SLE are in Phase II. Therapies in development for SLE focus on a wide variety of targets. The majority of pipeline drugs are administered via the subcutaneous route, with the remainder being intravenous, oral, and intramuscular formulations.
- High-impact upcoming events for drugs in the SLE space comprise topline Phase II trial results for evobrutinib, lenabasum, iscalimab, and BMS-986165; topline Phase IIa trial results for RSLV-132; topline Phase III trial results for Benlysta and anifrolumab; and an expected patent expiration for INV103.
- The overall likelihood of approval of a Phase I SLE asset is 4.5%, and the average probability a drug advances from Phase III is 40%. Drugs, on average, take 9.6 years from Phase I to approval, compared to 9.0 years in the overall autoimmune/immunology space.
- The distribution of clinical trials across Phase I–IV indicates that the majority of trials for SLE have been in the early and midphases of development, with 68% of trials in Phase I–II, and 32% in Phase III–IV.
- The US has a substantial lead in the number of SLE clinical trials globally. Germany leads the major European markets, while South Korea has the top spot in Asia.
- Clinical trial activity in the SLE space is dominated by completed trials. GlaxoSmithKline has the highest number of completed clinical trials for SLE, with 29 trials.
- GlaxoSmithKline leads industry sponsors with the highest overall number of clinical trials for SLE, followed by AstraZeneca.
CONTENTS
6 OVERVIEW
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
8 Disease definition
8 Symptoms
8 Patient subtypes
8 Risk factors
9 Diagnosis
10 TREATMENT
10 Nonsteroidal anti-inflammatory drugs (NSAIDs) and pain relievers
10 Corticosteroids
10 Antimalarial drugs
10 Immunosuppressive agents
11 Anticoagulants
11 Monoclonal antibodies
11 Repository corticotropin injection
12 EPIDEMIOLOGY
13 MARKETED DRUGS
15 PIPELINE DRUGS
22 RECENT EVENTS AND ANALYST OPINION
22 BIIB059 for SLE (December 3, 2019)
23 Multiple Drugs for SLE (October 24, 2019)
24 Anifrolumab for SLE (August 29, 2019)
25 CC-11050 for SLE (August 26, 2019)
26 Lupuzor for SLE (June 28, 2019)
27 IFNa Kinoid for SLE (April 6, 2019)
29 KEY UPCOMING EVENTS
30 PROBABILITY OF SUCCESS
31 LICENSING AND ASSET ACQUISITION DEALS
31 AbbVie Pays $60m To Option Alpine’s Lupus Candidate
32 REVENUE OPPORTUNITY
33 CLINICAL TRIAL LANDSCAPE
34 Sponsors by status
35 Sponsors by phase
36 Recent events
38 BIBLIOGRAPHY
38 Prescription information
40 APPENDIX
LIST OF FIGURES
15 Figure 1: Overview of pipeline drugs for SLE in the US
15 Figure 2: Pipeline drugs for SLE, by company
16 Figure 3: Pipeline drugs for SLE, by drug type
16 Figure 4: Pipeline drugs for SLE, by classification
23 Figure 5: BIIB059 for SLE (December 3 2019): Phase II – LILAC
25 Figure 6: Anifrolumab for SLE (August 29, 2019): Phase III – TULIP SLE 2 (IV)
29 Figure 7: Key upcoming events in SLE
30 Figure 8: Probability of success in the SLE pipeline
33 Figure 9: Clinical trials in SLE
33 Figure 10: Top 10 drugs for clinical trials in SLE
34 Figure 11: Top 10 companies for clinical trials in SLE
34 Figure 12: Trial locations in SLE
35 Figure 13: SLE trials status
36 Figure 14: SLE trials sponsors, by phase
LIST OF TABLES
14 Table 1: Marketed drugs for SLE
17 Table 2: Pipeline drugs for SLE in the US
22 Table 3: BIIB059 for SLE (December 3, 2019)
23 Table 4: Multiple Drugs for SLE (October 24, 2019)
24 Table 5: Anifrolumab for SLE (August 29, 2019)
26 Table 6: CC-11050 for SLE (August 26, 2019)
27 Table 7: Lupuzor for SLE (June 28, 2019)
28 Table 8: IFNa Kinoid for SLE (April 6, 2019)
32 Table 9: Historical global sales, by drug ($m), 2015–19
32 Table 10: Forecasted global sales, by drug ($m), 2020–24
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Disease Analysis: Acute Myeloid Leukemia (AML) 
Sign up to the